SEC Form 4 · accession 0001127602-17-010305

BIOGEN INC. · BIIB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP Pharmaceutical Oper & Tech

Period of report

Mar 1, 2017

Accepted (ET)

Mar 3, 2017 · 6:07 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875045

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 1, 2017	M	481	$0.00	A	718	D
Common Stock	Mar 1, 2017	F	157	$293.26	D	561	D
Common Stock	Mar 1, 2017	A	2,730	$0.00	A	3,291	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Unit^F2,F3	$0.00	Mar 1, 2017	M	481	D	—	Mar 1, 2019	Common Stock	481	2,055	D
Restricted Stock Unit^F4,F3	$0.00	Mar 1, 2017	J	363	D	—	Mar 1, 2019	Common Stock	363	1,692	D

F1Includes 27.114 shares acquired under the Biogen Inc. employee stock purchase plan on 9/30/2016 and 12/30/2016.
F2This award was previously reported as covering 2,480 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017
F3The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F4This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.